Clinical Trial Update: Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated whether mometasone furoate can prevent radiation dermatitis in patients undergoing radiation therapy for breast cancer or ductal carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ
• Radiation Dermatitis

Drugs mentioned

• Elocon (mometasone furoate)

Snippet

Sponsor: North Central Cancer Treatment Group | Conditions: Breast Cancer, Dermatologic Complications | Phase 3 | Status: COMPLETED | Results posted: 2015-02-12